# Vaccine Therapy in Treating Patients Receiving Trastuzumab For HER2-Positive Stage IIIB-IV Breast Cancer

> **NCT00343109** · PHASE2 · COMPLETED · sponsor: **University of Washington** · enrollment: 38 (actual)

## Conditions studied

- HER2-positive Breast Cancer
- Male Breast Cancer
- Stage IIIB Breast Cancer
- Stage IIIC Breast Cancer
- Stage IV Breast Cancer

## Interventions

- **BIOLOGICAL:** HER-2/neu intracellular domain protein
- **PROCEDURE:** leukapheresis
- **OTHER:** laboratory biomarker analysis
- **BIOLOGICAL:** sargramostim
- **OTHER:** immunologic technique
- **BIOLOGICAL:** synthetic tumor-associated peptide vaccine therapy

## Key facts

- **NCT ID:** NCT00343109
- **Lead sponsor:** University of Washington
- **Sponsor class:** OTHER
- **Phase:** PHASE2
- **Study type:** INTERVENTIONAL
- **Status:** COMPLETED
- **Start date:** 2004-03
- **Primary completion:** 2015-06
- **Final completion:** —
- **Target enrollment:** 38 (ACTUAL)
- **Last updated:** 2020-02-12

## Collaborators

- [object Object]

## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT00343109

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT00343109, "Vaccine Therapy in Treating Patients Receiving Trastuzumab For HER2-Positive Stage IIIB-IV Breast Cancer". Retrieved via AI Analytics 2026-06-24 from https://api.ai-analytics.org/clinical/NCT00343109. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*